Nduka Obi Ossai, MD
Nephrology · Las Cruces, NMNPI 1770883720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $332 and has fallen 52.4% since, to $158 in 2025. That places this record below the midpoint for nephrology clinicians in NM, where the typical reported total is $1,114.
Across 52 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$178
- Vifor Pharma, Inc.$138
- AstraZeneca$120
- Bayer$104
- Travere Therapeutics, Inc.$102
- Amgen$86
- plus $389 from 12 others
What the payments were for
- Food & beverage$1,09798%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 10 | $178 |
| Vifor Pharma, Inc. | 7 | $138 |
| AstraZeneca(2 entities) | 6 | $120 |
| Bayer | 5 | $104 |
| Travere Therapeutics, Inc. | 4 | $102 |
| Amgen(2 entities) | 4 | $86 |
| Nxstage Medical, Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| GSK | 2 | $40 |
| Sanofi | 2 | $36 |
| Lilly USA, LLC | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $29 |
| Akebia Therapeutics Inc | 1 | $27 |
| Medtronic | 1 | $27 |
| Novo Nordisk | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $14 |
How this compares
$1,117 in reported general payments places this provider in the 50th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 29 | $137,057 |
| JardianceEmpagliflozin | 53 | $55,040 |
| FarxigaDapagliflozin Propanediol | 51 | $42,602 |
| VeltassaPatiromer Calcium Sorbitex | 35 | $40,836 |
| Sevelamer Carbonate | 141 | $25,166 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $4,021 |
| ProsolParenteral Amino Acid 20% No.1 | 11 | $1,862 |
| Midodrine Hcl | 40 | $1,721 |
| Potassium Chloride | 83 | $1,287 |
| Furosemide | 229 | $1,200 |
| Hydralazine Hcl | 114 | $1,168 |
| Bumetanide | 23 | $939 |
| Amlodipine Besylate | 126 | $688 |
| Losartan Potassium | 101 | $678 |
| Nifedipine ErNifedipine | 34 | $624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $178 | $137,05729 claims |
| AstraZenecaFarxiga, Lokelma | $120 | $46,62463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Las Cruces
- Jose HenaoLas Cruces$31K
- Claudio Perez-LedezmaLas Cruces$4K
- Osvaldo DelavegaLas Cruces$1K
- Lucia CorroLas Cruces$1K
- Satyaki BanerjeeAlbuquerque$260K
- Catalina VoinescuSanta Fe$41K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.